Compare MCHX & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MCHX | RVPH |
|---|---|---|
| Founded | 2003 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 70.3M | 71.0M |
| IPO Year | 2004 | N/A |
| Metric | MCHX | RVPH |
|---|---|---|
| Price | $1.63 | $0.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $3.33 |
| AVG Volume (30 Days) | 32.0K | ★ 4.4M |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $46,494,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.70 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.26 | $0.25 |
| 52 Week High | $2.31 | $2.95 |
| Indicator | MCHX | RVPH |
|---|---|---|
| Relative Strength Index (RSI) | 48.29 | 58.18 |
| Support Level | $1.60 | $0.60 |
| Resistance Level | $1.70 | $0.77 |
| Average True Range (ATR) | 0.08 | 0.05 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 66.67 | 61.01 |
Marchex Inc harnesses the power of AI and conversational intelligence to provide actionable insights aligned with prescriptive vertical market data analytics, driving operational excellence and revenue acceleration. Marchex enables executive, sales, and marketing teams to optimize customer journey experiences across communications channels, enabling enterprise strategies, empowering businesses to increase revenue through informed decision-making and strategic execution.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.